Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Alamir1111on May 29, 2024 12:55pm
147 Views
Post# 36062589

RE:RE:RE:RE:RE:Management Information Circular

RE:RE:RE:RE:RE:Management Information CircularSo the temporarily  appointed  auditor till this year's agm needs to be voted full tome I guess


NOTICE IS HEREBY GIVEN that, on the advice of the Audit Commitee of Theralase Technologies Inc. (the “Corporation”), the Board of Directors of the Corporation resolved as of January 12, 2024, that: (i) the resignation of the Predecessor Auditor, with effect from January 12, 2024, as auditor of the Corporation be accepted, and (b) the Successor Auditor be appointed as auditor of the Corporation effective as of January 12, 2024, to hold office until the next annual meeting of the shareholders of the Corporation at a remuneration to be fixed by the Board of Directors of the Corporation. 


Appointment Of Auditor
Effective January 12, 2024, AGT Partners LLP Chartered Professional Accountants (“AGT Partners”) were appointed auditors of the
Corporation following the resignation of Richter LLP (“Richter”) at the request of the Corporation. The termination of Richter and the
appointment of AGT Partnersin its place was recommended by the audit committee of the Board and approved by the Board. Attached
to this Management Information Circular as Schedule “E” is a copy of the reporting package, as defined in National Instrument 51- 102
Continuous Disclosure Obligations (“NI 51-102”), that was filed with the requisite securities regulatory authorities. The reporting
package consists of (i) the notice of change of auditor advising that the Corporation appointed AGT Partners as the auditors of the
Corporation effective January 12, 2024 to fill the vacancy caused by the termination of Richter on January 12, 2024, that no reports of
Richter on any of the Corporation’s financial statements expressed a modified opinion, and that there has been no reportable events,
as defined by NI 51-102; and (ii) a letter from each of Richter as former auditor and AGT Partners as successor auditor confirming their
agreement with the information contained in notice of change of auditor.
Shareholders will be requested to appoint AGT Partners as auditors of the Corporation to hold office until the next annual meeting of
Shareholders and to authorize the directors of the Corporation to fix their remuneration.
In the absence of a contrary specification made in the Instrument of Proxy, the persons named in the accompanying Instrument of
Proxy intend to vote for the appointment of AGT Partners as auditors of the Corporation to hold office until the next Annual General
and Special Meeting of Shareholders and to authorize the Directors to fix their remuneration.
Approval of the foregoing resolution
will require the affirmative vote of a majority of the votes cast by holders of Common Shares present in person or represented by
proxy at the Meeting.
Re-Approval of the Corporation’s 2004 Stock Op
<< Previous
Bullboard Posts
Next >>